UBS Raises McKesson (MCK) Price Target to $1,200
UBS has reaffirmed its Buy rating on McKesson with a new price target of $1200, a 19.59% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
UBS raised its price target on McKesson Corporation ($MCK) to $1,200 from $1,080 on October 16, 2026, and rates the stock "Buy".
MCK
McKesson Corporation
Key Points
- On October 16, 2026, UBS reiterated its Buy rating on McKesson Corporation (NYSE: MCK) and raised its price target to $1200 from $1080.
- UBS's $1,200 price target implies 19.59% upside from McKesson Corporation's ($MCK) current $1,003.46 share price.
- As of October 16, 2026, McKesson's stock was recently trading around $1003.46, which is about 16.4% below UBS's new target.
- The company reported a trailing twelve-month revenue of approximately $411 billion and a net margin of 1.1%.
Get $MCK trade alerts by text
We text you when insiders, Congress or big funds trade $MCK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated McKesson Corporation alert may contain errors. Disclosures
UBS has reaffirmed its Buy rating on McKesson Corporation (NYSE: MCK) on October 16, 2026, raising its price target to $1200 from the previous target of $1080. This rating comes as McKesson continues to show strong performance in the healthcare sector.
UBS vs. the S&P 500
Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in McKesson
Several institutional investors have adjusted their positions in McKesson recently. Blackrock Inc. reduced its stake by 623,450 shares, ending with 10,795,054 shares valued at about $10.8 billion. Vanguard Capital Management LLC trimmed its position by 107,468 shares, bringing its total to 7,853,137 shares worth approximately $7.9 billion. State Street Corporation also decreased its holdings slightly, with a reduction of 4,585 shares, resulting in 5,727,118 shares valued at about $5.8 billion. Meanwhile, Morgan Stanley increased its stake significantly by 3,006,523 shares, totaling 5,306,142 shares worth approximately $5.3 billion.
McKesson Corporation Stock Up 14.7%
McKesson shares were recently trading around $1003.46 as of October 16, 2026. This price is about 16.4% below UBS's new target of $1200, indicating potential upside if the stock reaches the target. The stock has shown resilience, and its performance will be closely watched as the next earnings report approaches.
$MCK price target
McKesson Corporation daily closes and this analyst's $1,200 target. Not advice.
Recent Earnings
In its trailing twelve months, McKesson reported revenue of approximately $411 billion, with a net margin of 1.1%. The company's next earnings report is scheduled for November 4, 2026, and investors will be looking for updates on growth and profitability.
Insider Buying and Selling at McKesson Corporation
Recently, there have been several insider transactions at McKesson. Chief Executive Officer Brian Scott Tyler sold 8,463 shares on June 17, 2026, at an average price of $775.13, totaling about $6.56 million. He again sold the same number of shares on July 7, 2026, at $793.56, amounting to about $6.72 million. Additionally, Director Bradley E. Lerman sold 301 shares on August 10, 2026, for $268,590, and Officer Napoleon B. Rutledge Jr. sold 111 shares on September 8, 2026, for about $98,951.
Analysts Set New Price Targets
On October 16, 2026, UBS maintained its Buy rating on McKesson with a new price target of $1200, up from $1080. This comes after several other analysts made updates, including Barclays, which maintained an Overweight rating with a target of $1000, and Leerink Partners, which kept an Outperform rating with a target of $1070.
About McKesson Corporation
McKesson Corporation provides healthcare services in the U.S. and internationally. It operates through segments like North American Pharmaceutical and Medical-Surgical Solutions, focusing on improving healthcare delivery and efficiency. This context is crucial as the company navigates a dynamic healthcare landscape.
Bottom Line
Investors should keep an eye on McKesson as it approaches its next earnings date on November 4, 2026. UBS's updated price target reflects confidence in the company's future performance, but the stock is currently trading below this target. Further institutional movements and insider transactions will also be important to watch.
Related Filing Alerts
Source: UBS's rating change on $MCK (Oct 16, 2026). Written by software, not financial advice. How we make alerts